Drug intelligence / Profile preview

acetyl-L-carnitine + methylphenidate

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral

Overview

This combination consists of acetyl-L-carnitine (ALC), a naturally occurring compound important for energy metabolism and fatty acid synthesis, and methylphenidate, a central nervous system stimulant commonly used to treat attention-deficit/hyperactivity disorder (ADHD). The combination has been studied as a potential treatment for ADHD in children and adolescents, with acetyl-L-carnitine potentially serving as an adjunctive therapy to methylphenidate.

Other names: ALC + methylphenidate

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on acetyl-L-carnitine + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetyl-L-carnitine + methylphenidate.

Explore the full profile